Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
1999-05-07
2009-10-06
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S142100, C424S143100, C424S152100, C424S171100, C435S069100, C435S320100, C530S387300, C530S388100, C530S388220, C530S388250, C530S388700, C530S388750, C536S023530, C536S024330
Reexamination Certificate
active
07597889
ABSTRACT:
Disclosed are binding molecules which are recombinant polypeptides containing: (i) a binding domain capable of binding a target molecule, and (ii) an effector domain having an amino acid sequence substantially homologous to all or part of a constant domain of a human immunoglobulin heavy chain; characterized in that the binding molecule is capable of binding the target molecule without triggering significant complement dependent lysis, or cell mediated destruction of the target, and more preferably wherein the effector domain is capable of specifically binding FcRn and/or FcγRIIb. These are generally based on chimeric domains which are derived from two or more human immunoglobulin heavy chain CH2 domains domains. In preferred embodiments the regions 233-236, and 327-331, are modified, as are further residues to render the molecule null allotypic. Also disclosed are nucleic acids, host cells, production processes and materials, and uses. Pharmaceutical preparations are also disclosed.
REFERENCES:
patent: 5624821 (1997-04-01), Winter et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 5846534 (1998-12-01), Waldmann et al.
patent: 6015555 (2000-01-01), Friden
patent: 6194551 (2001-02-01), Idusogie et al.
patent: WO 92/16562 (1992-10-01), None
patent: WO 93/04173 (1993-03-01), None
patent: 94/28027 (1994-12-01), None
patent: WO94/29351 (1994-12-01), None
patent: 95/05468 (1995-02-01), None
patent: WO 95/05468 (1995-02-01), None
patent: 98/05787 (1998-02-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Kuby et al, 1994, Immunology, Second edition, pp. 86-96.
Riechmann et al, 1988, Nature 332: 323-327.
Greenwood et al, Eur J Immunol 23: 1098-1104, 1993.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Griffin et al, Blood 86: 4430, Dec. 1995.
Warmerdam et al, “A Single Amino Acid in the Second Ig-Like Domain of the Human Fcγ Receptor II is Critical for Human IgG2 Binding”, The Journal of Immunology 147(4):1338-1343 (1991).
Warmerdam et al, “Interaction of a human FcγRIIb1 (CD32) isoform with murine and human IgG subclasses”, International Immunology 5(3):239-247 (1992).
Armour et al, “Recombinant IgG Lacking FcγRI Binding and Complement/Chemiluminescence Activation”, 5thEuropean Symposium on Platelet and Granulocyte Immunobiology, May 9-12, 1998.
Clark et al, “IgG Effector Mechanisms”, Chem. Immunol. 65:88-110 (1997).
Morgan et al, “The N-terminal end of the CH2 domain of chimeric human IgG1 and anti-HLA-DR is neccessary for C1q, FcγRI and FcγRIII binding”, Immunology 86:319-324 (1995).
Chappel et al, “Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies”, Proc. Natl. Acad. Sci. USA 88:9036-9040 (1991).
Armour K.L. et al.: “Recombinant human IgG molecules lacking Fc. gamma. receptor l binding and monocyte triggering activities.” European Journal of Immunology, (Aug. 1999) 29/8 pp. 2613-2624.
Cole M.S. et al.: “Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells” The Amerian Association of Immunologists pp. 3613-3621, 1997.
Mueller J.P. et al. “Humanized porcine Vcam-specific monoclonal antibodies with chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells” Alexion Pharmaceuticals Inc., Departments of Immunobiology and Molecular Development Molecular Immunology, vol. 34, No. 6, (1997) pp. 441-452.
Canfield and Morrison, “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region”, J. Exp. Med. 173:1438-1491 (1991).
Tao et al, The Differential Ability of Human IgG1 and IgG4 to Activate Complement Is Determined by the COOH-terminal Sequence of the CH2 Domain, Brief Definitive Report, J. Exp. Med., vol. 173, Apr. 1991, pp. 1025-1028.
Duncan and Winter (1988. Nature, 332: 738-740).
Valim and Lachmann (1991. Clin Exp Immunol, 84: 1-8).
Sarmay et al. (1992. Mol Immunol, 29: 633-639).
Michaelsen et al. (1992. Mol Immunol, 29: 319-326 ).
Dorai et al. (1992. Mol Immunol, 29: 1487-1491).
Wright and Morrison (1994. J Exp Med, 180: 1087-1096 ).
Brekke et al. (1995, Immunol Today, 16: 85-90 ).
Ward and Ghetie (1995. Therapeutic Immunology, 2: 77-94).
Armour Kathryn Lesley
Clark Michael Ronald
Williamson Lorna McLeod
Cambridge Enterprise Limited
Huynh Phuong
Nixon & Vanderhye P.C
LandOfFree
Binding molecules derived from immunoglobulins which do not... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Binding molecules derived from immunoglobulins which do not..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Binding molecules derived from immunoglobulins which do not... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4130225